河南治羊癫疯那家医院好河南癫痫医院诊断方法有哪些,菏泽癫痫病能治愈偏方,山东济南癫痫病医院的评价,滨州治疗羊癫疯的最快方法,山东省治疗儿童羊羔疯病医院,淄博治疗癫痫多少钱好,泰安小儿羊羔疯好的治疗方法

The Trump administration has formally asked the Federal Communications Commission (FCC) to develop regulations that could apply to Facebook, Twitter and other such platforms.It's a key step toward President Donald Trump fulfilling his executive order to regulate social media.The order asks the FCC to clarify a section of law that has shielded tech companies from much litigation over internet content since 1996.The FCC — which is reviewing the Administration's petition — now has to decide whether to agree with the president's call for oversight or not.Legal experts say the agency has traditionally avoided regulating internet companies in the past. 662

The roads around your child's or grandchild's school may not be as safe as you think.One in three drivers are doing unsafe things, like being on their cell phone, in school zones.New research from Zendrive says from 4 - 5 p.m. is the most dangerous time to be on or near roads around schools.So that's something to keep in mind, even if you're not picking up kids.It says afternoon pick-up is 40 percent more dangerous than the morning pick-up.The company mapped out the areas around 75,000 schools across the country to see which states are the safest.States in green are the safest overall around schools. And red is the least safe.You can see a breakdown by county and check out your child's specific school here. 754

The Trump administration will end the protected immigration status of thousands of Central Americans who have been living in the US nearly two decades, urging Congress to act if it wants to spare those individuals from being uprooted.Department of Homeland Security acting Secretary Elaine Duke has decided to terminate Temporary Protected Status for Nicaragua with a 12-month delay, the department announced Monday night. DHS also said Duke has not been able to reach a decision on Honduras despite different agencies' input, triggering an automatic six-month extension. At the end of that six-month window, the homeland security secretary will make a decision to terminate or further extend the status.The Trump administration has signaled a desire to wind down the protections of Temporary Protected Status, which is an immigration status allowed by law for certain countries experiencing dire conditions, such as a natural disaster, epidemic or war. TPS protects individuals from deportation and authorizes them to work in the US. Without TPS, those individuals revert to whatever status they had previously -- which could leave large numbers as undocumented immigrants.In encouraging Congress to act if it wants to extend those protections permanently, the Trump administration echoed its move in ending the popular Deferred Action for Childhood Arrivals program, which protects hundreds of thousands of young undocumented immigrants brought to the US as children and which President Donald Trump decided to sunset this fall.Both decisions were due by Monday, as the status was set to expire January 5. There is a 60-days-in-advance requirement by law to make a determination on extending or terminating Temporary Protected Status.The roughly 5,300 individuals from Nicaragua affected by this decision have lived in the US roughly 20 years: To qualify for TPS, Nicaraguans must have been living in the US continuously since January 5, 1999, after Hurricane Mitch devastated the country.DHS officials told reporters that Duke did not yet have enough information to make a decision on the 86,000 individuals covered under the Honduran protections, which by law triggers a six-month extension. Hondurans also have to have been living in the US continuously since January 5, 1999 to qualify, also due to Hurricane Mitch.The move was being closely watched and heavily lobbied on both sides.Though the administration says it is evaluating each country on its own, it has been more aggressive than previous administrations in evaluating only whether conditions have improved from what triggered the initial designation, regardless of dire conditions continuing due to other causes. That has the support of conservatives like Senate Judiciary Chairman Chuck Grassley, who wrote DHS last week urging them to not perpetually renew TPS.In the next few months, the status of hundreds of thousands of TPS recipients will be up for decision. The Trump administration has already terminated the status for Sudan, extended protections for South Sudan, and given itself an extra six months to decide on protections for roughly 58,000 Haitians. That will be the next decision due, at the end of the month. When former Homeland Security Secretary John Kelly extended Haitian TPS another six months over the summer, he encouraged recipients to either apply for status under some other means or prepare to depart the US.In extending Nicaraguan protections for a final 12 months, DHS officials on a call with reporters urged those recipients to "seek an alternative lawful immigration status in the United States, if eligible, or, if necessary, arrange for their departure."Coming up early next year is also a decision for El Salvador, with roughly 260,000 people covered from that country, who have lived in the US more than 15 years.One official also called on Congress to act if they want individuals to remain permanently. Democrats have heavily lobbied DHS to preserve the protections, as have advocacy groups and business groups like the US Chamber of Commerce."Only Congress can legislate a permanent solution and provide those in an otherwise perpetually temporary status with a certain future," the official said.Democrats were quick to call out the administration's move. The Congressional Hispanic Caucus called on Congress to act following the administration's "reckless" action."The Trump administration's irresponsible decision to end TPS for Nicaraguans will tear apart families and upend the lives of these hard-working individuals," CHC Chairwoman Michelle Lujan Grisham said in a statement. "These immigrants have lived in the United States for nearly 20 years and have raised US citizen children, contributed to our economy and enriched our communities. Deporting families who are contributing to the economic and social fabric of our nation isn't leadership; it's a reckless and callous abuse of power."  4920

The U.S. regulators who will decide the fate of COVID-19 vaccines are taking an unusual step: Asking outside scientists if their standards are high enough.The Food and Drug Administration may have to decide by year’s end whether to allow use of the first vaccines against the virus. Thursday, a federal advisory committee pulls back the curtain on that decision process, debating whether the guidelines FDA has set for vaccine developers are rigorous enough.“We will not cut corners, and we will only use science and data to make that determination,” FDA Commissioner Stephen Hahn pledged at a meeting of the Milken Institute Wednesday.Exactly how much data his agency needs to be sure a vaccine is safe and effective is a key question for the advisers. An even bigger one: If the FDA allows emergency use of a vaccine before final testing is finished, will that destroy chances of ever learning just how well that shot -- and maybe competitors still being studied -- really work?“We can’t lose sight of the fact that it is in our societal interest to see these trials to completion,” said Dr. Luciana Borio, a former FDA acting chief scientist who will be watching the advisers’ debate.Plus, multiple vaccines are being studied -- shots made with different technologies that each have pros and cons.“The first vaccine is not necessarily the best vaccine,” cautioned Dr. M. Miles Braun, a former FDA scientist now with Georgetown University School of Medicine. If the trials aren’t allowed to finish, it may be difficult or impossible to ever know for sure.It’s a critical moment in FDA’s 114-year history. The government has spent billions to race a vaccine through a research process that usually takes years, and FDA faces unprecedented pressure from the Trump administration, fueling public skepticism that politics could overrule science.Interest is so high, FDA is airing the meeting on YouTube. Here are some key issues the committee will discuss:HOW MUCH EVIDENCE IS NEEDED?FDA is requiring manufacturers to do studies of at least 30,000 people to prove if a vaccine protects and how safe it is. Those studies must include adequate numbers of people at highest risk from COVID-19 -- older adults, minorities and anyone with underlying health problems.FDA has made clear that any vaccine must be at least 50% effective. And while the studies are designed to run for two years, companies may get enough evidence the shots are protective -- in at least some people -- to stop the trials early and seek what’s called an “emergency use authorization” for wider vaccinations.Despite White House objections, the FDA told vaccine makers earlier this month not to seek that speedier review until they’ve tracked at least half their trial participants for two months. With other vaccines, that’s about the amount of time when major side effects crop up.That’s not long enough, said the head of the non-profit ECRI Institute, which reviews medical technology for hospitals and insurers. In comments submitted to the advisory committee, ECRI’s Dr. Marcus Schabacker said FDA should require six months of follow-up.“Doing any less would simply risk too much, and the consequences may be severe,” he wrote. “A weak vaccine that loses public trust could poison the well for epidemic control for many years.”WOULD EMERGENCY USE DERAIL FULL ANSWERS ABOUT VACCINES?Normally when a study ends because of evidence that a vaccine is working, the participants who got dummy shots are offered the real thing.But if FDA allows emergency use of a COVID-19 vaccine, that’s not the same as having full proof the shot works, Borio cautioned.And if the participants in the placebo group are immediately offered the real shot, researchers may not be able to get answers about all the high-risk groups in the study — or tell how long the vaccine’s protection lasts, a process expected to take many more months.But Pfizer Inc., which with Germany’s BioNTech is developing one of the leading candidates, told FDA that if it’s granted emergency use authorization, it “would have an ethical obligation” to alert study participants who got a placebo and allow them vaccine access. The company wants FDA to look into “other scientifically and statistically sound methods” to determine long-term safety and effectiveness.Pfizer’s stance is likely to face pushback. The Infectious Diseases Society of America states that FDA’s panelists “should insist” that vaccine developers “present a compelling case” for how they will complete their trials if FDA grants early authorization of their vaccine.Clearing a vaccine based on premature or faulty data “could cause more harm” by “further eroding public confidence in all vaccines,” the group said.It’s an unprecedented dilemma. The FDA has previously allowed emergency use of only one vaccine, a decades-old shot that in 2005 was authorized to prevent anthrax poisoning.This time around, multiple COVID-19 vaccines are in the pipeline. Pfizer competitor Johnson & Johnson cautioned that early FDA clearance of one vaccine could “jeopardize integrity” of other ongoing trials if patients decide to drop out to seek the first cleared shot instead.The company asked regulators to explain what options are available to ensure completion of all ongoing COVID-19 vaccine trials.WHAT ABOUT LONG-TERM SAFETY MONITORING?Even a study of 30,000 people cannot spot a side effect that only strikes 1 in 100,000. So the government is planning extra scrutiny of every COVID-19 vaccine to hit the market.At first there will be limited doses given to just certain high-risk people -- and those early recipients are to get text messages daily for the first week after vaccination, and then weekly out to six weeks, asking how they’re feeling.FDA also will be checking databases of electronic health records and insurance claims, looking for any red flags.“There’s a kind of tracking that has to take place here on a massive basis that hasn’t taken place before,” said Dr. Jesse Goodman of Georgetown University, a former director of the FDA’s vaccine and biologics center.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 6274

The United States State Department has lifted a worldwide Level 4 travel advisory which had been in place since the spring amid the spread of the coronavirus.A Level 4 advisory is the highest alert level at the State Department, which warns travelers of life-threatening risks.The State Department still has a number of Level 4 advisories across the globe, including neighboring Mexico.The change in status, however, might not have much impact on travelers as many countries have placed strict limits on non-essential travel from the United States. And with the United States still leading the world in coronavirus cases and deaths, Americans ability to travel internationally is expected to be limited for months to come. 730